Anocca has submitted its first clinical trial application (CTA) for conducting the Phase I/II VIDAR-1 trial to the EMA.

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

Real-world evidence (RWE) trials mainly involve observational data outside the traditional involvement of randomised ...

Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as ...

The announcement means the company will be pulling the plug on the CardinALS trial after its ALS drug failed to halt disease ...

Lexicon Pharmaceuticals has completed the enrolment of subjects for the multicentre Phase IIb PROGRESS trial of LX9211 to ...

Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had ...

MSD has reported that the Phase III ZENITH trial of WINREVAIR for pulmonary arterial hypertension met its primary endpoint.

The Phase III trial of AXS-12 showed results over placebo as the company looks towards a new drug application for its ...

AstraZeneca has reported positive results from a Phase III trial that evaluated Truqap combined with abiraterone and ADT for ...

The Global Coalition for Adaptive Research (GCAR) has executed an agreement to evaluate AstraZeneca's AZD1390 in the GBM ...

ArkBio has concluded enrolment and dosing for a Phase I trial of AK0610, to prevent RSV infection, particularly in vulnerable ...